Key facts
- It has raised $1.7M; the latest was Accelerator/Incubator in Jul 2025.
- Notable investors include DAYLI Partners, TBIC KAIST, Union Investment Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Livotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Livotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Livotech
Developer of drugs intended to provide treatment for various diseases. The company develops drugs that can treat different diseases using messenger ribonucleic acid targets, enabling doctors to treat genetic diseases by giving patients the correct version of a defective gene.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2020
- Employees
- 7
- Ownership
- Privately Held (backing)
Livotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Livotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Livotech in its N-PORT filings yet. We sweep new filings monthly.